Our Vision
A world where the early diagnosis and better treatment of cancer is within reach of everyone.
Our Focus
The development and commercialization of bladder cancer diagnostics and prognostic tests to address unmet clinical needs in the care of patients presenting with hematuria or being monitored for recurrent disease.
Our Capability
From discovery to market adoption. Our expertise spans the product life cycle: cancer genetics, molecular oncology, bioinformatics, clinical research, medical practice and industry engagement, market access and reimbursement, sales and marketing, quality systems and regulatory.
Our Culture
Our strength is in our people and we invest in their growth and success. We pride ourselves on our values-driven, diverse, and results focused culture.
A Global Cancer Diagnostics Company
Headquartered in New Zealand, Pacific Edge develops and commercializes Cxbladder – a suite of non-invasive genomic biomarker tests – to clinicians around the world through its wholly owned, ISO15189 compliant laboratories in New Zealand and CLIA/CAP/NYS certified laboratories in the United States.
Read MoreInvestor Center
Pacific Edge is listed on the NZX and ASX under the ticker PEB and provides investors with an opportunity to invest into the rapidly growing cancer diagnostic market. Here you will find all the information you need to make an informed investment decision and become a Pacific Edge shareholder.
Read MoreA New Standard of Patient Care
Cxbladder is a suite of advanced genomic biomarker tests optimized for the rule out and surveillance of bladder cancer.
With non-invasive urine-based sampling and the option of in-home sample collection, Cxbladder optimizes practice workflow while delivering the best patient experience possible.
Read MoreNews & Events
Latest news updates, announcements and calendar of events.
MEDICARE COVERAGE FOR TRIAGE AND TRIAGE PLUS CONFIRMED
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX/ASX: PEB) notes that the final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Triage Plus. The final LCD, 'Urine-based Biomarkers in Patients with Microhematuria' (L40378), establishes hematuria evaluation as a covered Medicare benefit and provides foundational medical policy for the use of validated urine-based biomarkers in the evaluation of intermediate risk microhematuria patients. The final LCD is scheduled to become effective in 45 days on 20 December 2026. [read more]
Read MoreeNews Subscription
Sign up to receive email notification of news and announcements from Pacific Edge.
Subscribe Here